Services Marketing: You Can’t Build A Strong Marketing Strategy On A Weak Foundation

CEO of Industry Standard Research Kevin Olson explains how marketers can elevate their credibility, the credibility of their strategy, and the overall impact of marketing plans in their organization. Is your services marketing strategy constantly being questioned, critiqued, and disrupted internally? Too often, marketers lack vital information to create an effective marketing strategy and your … Continued

Study Startup Technology Investment Pays Off

Chief Editor Ed Miseta at Clinical Leader speaks with Industry Standard Research President Andrew Schafer about ISR’s custom research report eClinical Technology Adoption and Challenges in Study Startup. My advice, based on the data we collected, would be to make sure everyone is clear as to the goals of the technology implementation. For example, is the … Continued

Decision-making Responsibilities When Outsourcing Late-Phase Studies

VP of Market Research at Industry Standard Research Kate Hammeke explains the importance of conducting decision-making process research for sales and marketing outreach. Market research categorized as DMP/DMU (decision-making process/decisionmaking unit) studies may be conducted qualitatively, via in-depth interview, or quantitatively, via web-based survey. When it comes to outsourcing aspects of pharmaceutical development and commercialization, … Continued

Decision-Makers Agree—Phase I Clinical Research is Becoming More Complex

Informing pharmaceutical drug developers, manufacturers, and service providers Raleigh, N.C. — October 16, 2018 — Industry Standard Research (ISR) announces the release of its newest report, “Phase I Study Trends and Market Outlook (2018-2022),” in which 143 Phase I decision-makers provide valuable insight into market size, factors that could affect the number of studies conducted … Continued

Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations

Editor Anna Rose Welch at Biosimilar Development speaks to VP of Industry Standard Research Kate Hammeke about our recent report Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition). Indeed, there are already 11 percent of respondents currently selling biosimilars to their own biologic. And of the 41 percent of respondents who are currently considering biosimilars … Continued

Biotrial and SGS Life Sciences Receive High Marks for Accessibility

Informing pharmaceutical drug developers, manufacturers, and service providers Raleigh, N.C. – September 27, 2018 – Industry Standard Research (ISR) has released a new report, the 10th edition of its CRO Quality Benchmarking – Phase I Service Providers series. ISR surveyed 305 decision-makers at sponsor organizations to gather their insights on topics such as service provider … Continued

CRO Growth Continues, ISR Projects More Growth to Come

Informing the drug development and pharmaceutical manufacturing industry. Raleigh, N.C. – September 25, 2018 – Industry Standard Research (ISR) has announced the newest edition of its CRO market analysis report “2018 CRO Market Size Projections: 2017-2022.” For this report, ISR has utilized publicly available information from biopharma, government, private, non-profit, and academic institutions as well as … Continued

Large CROs Stand Out in Post-marketing Pharmacovigilance

Informing pharmaceutical drug developers, manufacturers, and service providers. Raleigh, N.C. – September 24, 2018 – Industry Standard Research (ISR) has released a new report, the 10th edition of its CRO Quality Benchmarking – Phase IV Service Providers series. ISR surveyed 230 decision-makers at sponsor organizations to gather their insights on topics such as service provider brand perceptions and use, … Continued

Time To Silence Capacity Alarms For Bioprocessing?

Chief Editor Louis Garguilo at Outsourced Pharma speaks with VP of Industry Standard Research Kate Hammeke about the non-appearance of a long-anticipated capacity crunch for bioprocessing services. One thing is certain: When considering overall outsourcing capacity, there are mitigating factors at work in the marketplace. The most important is that the bigger drug sponsors have in … Continued

A Hypothetical Question About Outsourcing Services Leads To … More Questions?

VP of Market Research at Industry Standard Research Kate Hammeke reviews some interesting findings which arose from comparing a theoretical question’s responses to other survey results. The five most common answers to this unaided question offer no real surprises on their own: quality (49 percent), price/affordability (41 percent), timelines (32 percent), expertise (29 percent), and regulatory compliance … Continued

Clinical Outsourcing Models: Still A Lot Of Churn And Uncertainty

Chief Editor Ed Miseta at Biosimilar Development discusses ISR’s recent report Clinical Development Outsourcing Models (3rd Edition) with President of Industry Standard Research Andrew Schafer. Being the third edition of this report, we can really see how the clinical development industry has both changed and not changed over the past five years. One point that really struck … Continued

What Makes It So Hard To Select A CMO?

VP of Market Research at Industry Standard Research Kate Hammeke answers why sponsors regularly struggle with CMO selection as one of the most difficult parts of their outsourcing manufacturing activities. In it we asked participants an open-ended question: “In your opinion, what is the most difficult part of outsourcing manufacturing activities?” The write-in responses, in … Continued

Big Pharma CMOs win for Biologic API and Alcami Scores Highest for Biologic Drug Product

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Raleigh, NC – May 23, 2018 –Industry Standard Research’s (ISR’s) 3rd annual Biologic API Contract Manufacturer Quality Benchmarking report shows Big Pharma CMOs—AbbVie Contract Manufacturing, Boehringer Ingelheim, and CEPiA Sanofi—received the highest Overall Performance Scores for drug substance manufacturing. Also just released, ISR’s Biologic Drug Product … Continued

Accenture and Medpace Excel in Phase II/III Delivery Factors

Informing pharmaceutical drug developers, manufacturers, and service providers. Raleigh, N.C. – May 17, 2018 – Industry Standard Research (ISR) has released a new report, the 10th edition of its CRO Quality Benchmarking – Phase II/III Service Providers series. ISR surveyed 301 decision-makers at sponsor organizations to gather their insights on topics such as service provider … Continued

FLAMMA, Novasep and Alcami Win for Small Molecule Contract Manufacturing Performance

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – May 15, 2018 –  Industry Standard Research’s (ISR’s) annual Small Molecule API Contract Manufacturer Quality Benchmarking report reveals that FLAMMA and Novasep received the highest Overall Performance Scores based on customer expectations. The Small Molecule Drug Product Contract Manufacturer Quality Benchmarking report, also just … Continued

CRO Selection Taken Seriously

VP of Market Research at Industry Standard Research Rebecca McAvoy explains why sponsors need to give an appropriate amount of attention toward choosing their service providers. The remaining 35 percent at least slightly disagreed with the statement, meaning they anticipate some level of change to their organization’s mix of CROs over the next few years. Thirty-five percent … Continued

Brand Strength And The Contract Manufacturing Competitive Landscape

VP of Market Research at Industry Standard Research Kate Hammeke explains how important it is to know your business’ competitive landscape and how that impacts your buying audience, and then to use that knowledge to inform your marketing strategies. For example, if we look at brand strength, which measures the drop-off of potential customers at … Continued

Outsourcing Relationships Benefit From Aligning CMO Expertise With Sponsor Needs

VP of Market Research at Industry Standard Research Kate Hammeke discusses how both sponsors and CMOs can improve their understanding of the link between selection priorities and performance strengths, and how aligning these attributes can impact the client-vendor relationship. It’s more than just the absence of a “magic attribute” that leads to successful sponsor-CMO relationships; … Continued

Large Or Small Molecule: Drug Sponsors Share API Outsourcing Philosophy

Chief Editor Louis Garguilo at Outsourced Pharma asks “Are there strategic and tactical differences for [Large or Small Molecule] programs when outsourcing to CMOs?” In the small molecule report (SMR), 70% of biopharma companies that use “preferred provider lists” responded that 1 to 5 CMOs make up that list; 20% said it was between 6 … Continued

Don’t Let Insufficient Data Undermine Your CMO & CRO Selection Processes

CEO of Industry Standard Research Kevin Olson offers three tips to strengthen your selection process with third-party performance benchmarking. Selecting a CMO or CRO is stressful, expensive, and time-consuming. The complexity of these supplier organizations makes them difficult to evaluate. Far too often, decision makers lack vital information to support selection decisions. But the consequences … Continued

ISR CUSTOMERS